Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2012	Mar. 20, 2015	Feb. 02, 2015	Apr. 12, 2013
Commitments and Contingencies Disclosure [Abstract]
Cancellation of company common shares held by Plaintiff				103,030,303
Satisfaction of convertible indebtedness held by Plaintiff				$ 17,000
Limitation on conversion of outstanding common stock				9.99%
Convertible Note to plaintiff, payable April 1, 2016			$ 300,000
Payment for consideration of note conversion			$ 52,500
Conversion discount rate			55.00%
Settlement with PRI Parties, payment per month	$ 1,000
Regen Biopharma monthly sublease fee to HBRI		$ 400
Regen Biopharma monthly research agreement fee		$ 2,700